Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Frazier's Commitment to Early-Stage Device Dealmaking Pays Off

This article was originally published in Start Up

Executive Summary

Frazier Healthcare Ventures has never been one to faddishly follow the flow of money in or out of medical device investing, maintaining its commitment to invest in this space. Indeed, the firm recently shifted its focus to concentrate on more early-stage medical device deals, a strategy that appears to be paying off.

You may also be interested in...



Medtech Investing 2009: What's Changed?

The medical device industry is undergoing a crisis of funding, but not of confidence, according to a panel of investors convened at Windhover's recent medtech conference, In3 West,. The conference panel sought to explore how the medical device investment community is operating in these troubled times, how they will invest going forward, and how they will support their companies if things don't improve. We were especially curious to know if the funding challenges that start-ups face are really due to the overall dire economy, or if that dark cloud merely masks changing fundamentals in the medical device industry that are making it more difficult for companies to find funding, gain FDA approval, and enjoy a healthy exit. Our panel weighs in on the matter.

Calypso Medical Technologies Inc.

Calypso Medical Technologies aims to improve on the precision of cancer radiation therapy with technology that, like global positioning systems, tracks actual organ positioning in real-time, enabling radiation therapists to accurately target the tumor or treatment area and avoid hitting healthy organs.

Advanced Bionics to Stimulate Growth for Boston Scientific

Investors approved of Boston Scientific's decision to purchase Advanced Bionics, which offers a wealth of new possibilities in areas in which BSC is already a leader--cardiology, urology, neurology, and gastroenteroloy. More than that, Advanced Bionics presents completely new and untapped businesses in neurostimulation.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel